Literature DB >> 17530187

The over-expression of p53 H179Y residue mutation causes the increase of cyclin A1 and Cdk4 expression in HELF cells.

Di Yang1, Yitao Qi, Qian Chen, Zhiqin Wang, Xi Jin, Jie Gao, Juanling Fu, Xilong Xiao, Zongcan Zhou.   

Abstract

Down-regulation of p53 expression has been found in a broad range of human cancers and cell proliferation disorders, indicating that p53 plays a key role in cell cycle regulation and tumor suppression. In our current study, we transfected human embryonic lung fibroblast (HELF) cells with pcDNA3-wild-type p53 (pcDNA3-wtp53) plasmid, or pcDNA3-H179Y-mutated p53 (pcDNA3-mtp53) plasmid that mimics the mutation found in some human lung tumors, and further studied the role of p53 in the regulation of cell proliferation. Over expression of wild-type p53 caused cell cycle arrest at G1 phase with reduced cell size, decreased expression of cyclin D3, cyclin E, Cdk2 and Cdk4, and increased expression of p21. In contrast, over expression of H179Y-mutant p53 promoted G1 to S phase transition with enlarged cell size and increased cyclin A1 and Cdk4 expression in HELF cells. These results indicate that mutation at the p53 H179Y residue up-regulates cyclin A1 and Cdk4 expression, and promotes HELF cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530187     DOI: 10.1007/s11010-007-9503-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  42 in total

Review 1.  p53: death star.

Authors:  K H Vousden
Journal:  Cell       Date:  2000-11-22       Impact factor: 41.582

2.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

3.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

Authors:  Silvia Di Agostino; Sabrina Strano; Velia Emiliozzi; Valentina Zerbini; Marcella Mottolese; Ada Sacchi; Giovanni Blandino; Giulia Piaggio
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

4.  Mutant p53 proteins bind DNA abnormally in vitro.

Authors:  S E Kern; K W Kinzler; S J Baker; J M Nigro; V Rotter; A J Levine; P Friedman; C Prives; B Vogelstein
Journal:  Oncogene       Date:  1991-01       Impact factor: 9.867

5.  Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes.

Authors:  N Gloushankova; V Ossovskaya; J Vasiliev; P Chumakov; B Kopnin
Journal:  Oncogene       Date:  1997-12-11       Impact factor: 9.867

Review 6.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

Review 7.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

Authors:  C Cadwell; G P Zambetti
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

8.  A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53.

Authors:  T Mukhopadhyay; J A Roth
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

9.  Wild-type human p53 activates the human epidermal growth factor receptor promoter.

Authors:  S P Deb; R M Muñoz; D R Brown; M A Subler; S Deb
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

10.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

View more
  3 in total

1.  Differentially Expressed mRNA Targets of Differentially Expressed miRNAs Predict Changes in the TP53 Axis and Carcinogenesis-Related Pathways in Human Keratinocytes Chronically Exposed to Arsenic.

Authors:  Laila Al-Eryani; Sabine Waigel; Ashish Tyagi; Jana Peremarti; Samantha F Jenkins; Chendil Damodaran; J C States
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

2.  Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival.

Authors:  Mauro Siragusa; William C Sessa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-23       Impact factor: 8.311

3.  Actionable mutations in canine hemangiosarcoma.

Authors:  Guannan Wang; Ming Wu; Martha A Maloneyhuss; John Wojcik; Amy C Durham; Nicola J Mason; David B Roth
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.